HeartSciences (HSCS) Liabilities and Shareholders Equity (2022 - 2025)

HeartSciences (HSCS) has 4 years of Liabilities and Shareholders Equity data on file, last reported at $4.2 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity changed N/A year-over-year to $4.2 million in Q4 2025, while the trailing twelve-month figure through Apr 2026 was $16.7 million (down 35.68% YoY) and the FY2025 annual result came in at $4.2 million, down 55.56% from the prior year.
• Liabilities and Shareholders Equity eased to $4.2 million in Q4 2025, from $6.0 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $10.8 million in Q1 2024 to a low of $2.1 million in Q2 2022.
• A 4-year average of $5.4 million and a median of $5.2 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity soared 228.38% — and 2025, when it plunged 55.56%.
• Tracing HSCS's Liabilities and Shareholders Equity over 4 years: stood at $4.8 million in 2022, then slumped by 50.36% to $2.4 million in 2023, then soared by 228.38% to $7.8 million in 2024, then tumbled by 45.7% to $4.2 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $4.2 million (Q4 2025), $6.0 million (Q4 2025), and $6.4 million (Q3 2025), per Business Quant data.